| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8209206 | Applied Radiation and Isotopes | 2016 | 13 Pages |
Abstract
A comparative analysis of the measured therapeutic response of different radiopharmaceuticals, based on previously published data, suggests that there is a lack of substantial differences in palliative efficacy among radiopharmaceuticals. However, when the comparative analysis adds factors such as patient's life expectancy, radionuclides' physical characteristics (e.g. tissue penetration range and half-life) and health economics to guide the rational selection of a radiopharmaceutical for palliative treatment of bone metastases, 177Lu and 188Re-labeled radiopharmaceuticals appear to be the most suitable radiopharmaceuticals for treatment of small and medium/large size bone lesions, respectively.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Francisco D.C. Guerra Liberal, Adriana Alexandre S. Tavares, João Manuel R.S. Tavares,